| Today's Big NewsNov 14, 2022 |
| By Andrea Park 2022 is undoubtedly a fraught time in the history of the women’s movement, but it is also an inspiring one, as people from every corner of the globe come together in support of the idea that women deserve equal rights. That double-edged sentiment echoes throughout this year’s list of the 20 fiercest women in life sciences. |
|
|
|
By Nick Paul Taylor Roche’s bet on the resurrection of Alzheimer’s disease candidate gantenerumab has flopped. The drug candidate failed to improve the rate of cognitive and functional decline in a pair of phase 3 clinical trials, delivering yet another blow to the field. |
By Andrea Park With only days to go until the former Theranos CEO is sentenced for fraud, attorneys for Holmes and for the U.S. government remain at loggerheads over a suitable punishment. |
By Heather Landi Bucking current market conditions, startup Maven Clinic scored $90 million in fresh funding to expand its services for women's health and family care. |
|
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now. 
|
|
By Max Bayer Roivant is cutting 12% of its staff as part of a larger effort to extend the company's cash runway into 2025. The company's statement did not elaborate on which spinoff companies would be affected. |
By Kevin Dunleavy Two years after acquiring a Pfizer biologics plant in Adelaide, Australia, Bridgewest Group has bought up another Pfizer manufacturing facility in the country. The San Diego-based investment firm has agreed to purchase a sterile injectables site near Perth. Two years ago, Pfizer said it had plans to close the site by 2023, endangering its 470 employees. |
By Gabrielle Masson The third quarter of 2022 has proved to be the season of biotech pipeline culls, with three more companies setting out plans this morning to shed programs in hopes that the lighter load will allow them to forge ahead in rocky market conditions. |
By Paige Minemyer Evernorth's MDLive is rolling out enhanced support for patients with chronic conditions as part of its virtual primary care platform, the telehealth provider announced Monday. |
By Andrea Park In a move that could potentially make it under the wire to rank among the biggest medtech M&A deals of 2022, Temasek Holdings is said to be considering a sale of its Advanced MedTech subsidiary. |
By Fraiser Kansteiner In a phase 2/3 trial of more than 500 adults, Moderna’s bivalent booster mRNA 1273.222 triggered a “significantly higher” immune response against the BA.4 and BA.5 omicron subvariants compared to an auxiliary dose of the company’s standard vaccine, mRNA-1273, which bears the commercial moniker Spikevax. |
By Annalee Armstrong Patients are living longer than expected in Sellas Life Sciences’ phase 3 trial for an acute myeloid leukemia drug. That’s great news for patients and has spurred a protocol amendment for the study—but the question remains: Is it because of the biotech’s drug? |
By Robert King CMS is pushing to resolve major gaps in health equity data as it moves to install new requirements for payers and providers on improving equity. |
By Conor Hale The collaboration will start with jointly identified oncology targets and then employ Exscientia’s AI platform to design small-molecule drugs. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Tuesday, November 29, 2022 | 2pm ET / 11am PT Process development of RNA-LNPs can be time consuming, cost prohibitive and require deep expertise in a field that is very dynamic and accelerating fast. Outsourcing gives you direct access to infrastructure, experience, and a team who has done this before and can quickly generate meaningful data taking the guesswork out of process development. Register now. 
|
|
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
